SAN DIEGO, June 04 2018 – At the American Society Clinical Oncology’s 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with pembrolizumab has activity for advanced solid tumors…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Polarispharmahttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngPolarispharma2018-06-06 14:53:502018-06-06 16:32:07Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Combination with Pembrolizumab for Advanced Solid Tumors
SAN DIEG0, June 03 2018 – Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX demonstrated promising efficacy for heavily pre-treated hepatocellular carcinoma (HCC) patients…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Polarispharmahttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngPolarispharma2018-06-06 14:25:132018-06-06 14:31:42Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 Plus FOLFOX in Hepatocellular Carcinoma
SAN DIEGO, May 31, 2018 – Polaris Group announced today that the first patient has been dosed in a phase 2 trial of ADI‑PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Polarispharmahttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngPolarispharma2018-05-31 09:47:332018-05-31 10:08:00Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI‑PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
SAN DIEGO, May 10, 2018 – Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy Platform, led by world-renowned immunotherapy pioneer Dr. James Allison, Dr. Padmanee Sharma, and Dr. Patrick Hwu, to design clinical studies and monitor biomarkers in immune functions associated with the therapies…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Polarispharmahttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngPolarispharma2018-05-10 09:26:262018-05-10 09:26:26Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research
SAN DIEGO, March 26, 2018 – Polaris Group announced today that its lead product ADI‑PEG 20 modulates PD-L1 expression via stimulating the release of IFN-a and -b in several tumor cell lines and the combination of ADI‑PEG 20 and PD-1/PD-L1 blockade abrogated tumorigenesis in a murine model according to research presented by a group from Barts Cancer Institute, London …
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Polarispharmahttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngPolarispharma2018-03-26 00:00:502018-05-08 08:50:16ADI‑PEG 20 and PD-1/PD-L1 Blockade Lead to Strong Anti-tumor Activity in ASS1- and PD-L1-negative Fibrosarcoma Murine Model
SAN DIEGO, January 10, 2018 – Polaris Group announced today that the combination of its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy cisplatin + pemetrexed doublet (PemCis) has shown promising clinical activity in an ongoing phase 1 study cohort of non-squamous non-small cell lung carcinoma (NSCLC) patients…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Polarispharmahttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngPolarispharma2018-01-10 00:00:582018-05-08 09:47:50Polaris Group’s ADI‑PEG 20 Shows Promising Clinical Activity in NSCLC When Combined with Standard First Line Chemotherapy Regimen
SAN DIEGO, September 12, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) demonstrated a good safety profile and an efficacy signal as monotherapy in a phase 2 trial in relapsed/refractory or poor-risk acute myeloid leukemia (AML) patients, as reported in the journal Scientific…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2017-09-12 14:03:002018-01-17 15:18:47Polaris Announces Results of a Phase 2 Trial of ADI‑PEG 20 in Relapsed/Refractory or Poor-risk Acute Myeloid Leukemia
SAN DIEGO, August 2, 2017 – Polaris Group announced today that the first patient has been dosed in its randomized, placebo-controlled, double blind phase 2/3 trial (ATOMIC-meso) in malignant pleural mesothelioma (MPM) patients. Patients will be randomized to receive ADI‑PEG 20 (pegylated arginine deiminase) or placebo in combination with pemetrexed…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2017-08-02 10:30:002018-01-17 15:16:49Polaris Group Announces Treatment of First Patient in Phase 2/3 Study of ADI‑PEG 20 Plus Cisplatin and Pemetrexed in Malignant Pleural Mesothelioma
SAN DIEGO, July 14, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI‑PEG 20 in combination with pembrolizumab for the treatment of advanced solid tumors. In addition to a global phase 2/3 trial in malignant plural mesothelioma featuring ADI‑PEG…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2017-07-14 15:05:412018-01-17 15:17:40Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 Plus Pembrolizumab in Advanced Solid Tumors
SAN DIEGO, June 5, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) is active in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM), including non-epithelioid MPM, which carries an unfavorable prognosis and historically responds poorly to…
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2017-06-05 15:07:422018-01-17 15:18:10Polaris Lead Therapeutic ADI‑PEG 20 in Combination with First Line Chemotherapy Is Active in Argininosuccinate Synthetase Deficient Mesothelioma
Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Combination with Pembrolizumab for Advanced Solid Tumors
NewsSAN DIEGO, June 04 2018 – At the American Society Clinical Oncology’s 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with pembrolizumab has activity for advanced solid tumors…
Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 Plus FOLFOX in Hepatocellular Carcinoma
NewsSAN DIEG0, June 03 2018 – Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX demonstrated promising efficacy for heavily pre-treated hepatocellular carcinoma (HCC) patients…
Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI‑PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma
NewsSAN DIEGO, May 31, 2018 – Polaris Group announced today that the first patient has been dosed in a phase 2 trial of ADI‑PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma, sponsored by Washington University…
Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research
NewsSAN DIEGO, May 10, 2018 – Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy Platform, led by world-renowned immunotherapy pioneer Dr. James Allison, Dr. Padmanee Sharma, and Dr. Patrick Hwu, to design clinical studies and monitor biomarkers in immune functions associated with the therapies…
ADI‑PEG 20 and PD-1/PD-L1 Blockade Lead to Strong Anti-tumor Activity in ASS1- and PD-L1-negative Fibrosarcoma Murine Model
NewsSAN DIEGO, March 26, 2018 – Polaris Group announced today that its lead product ADI‑PEG 20 modulates PD-L1 expression via stimulating the release of IFN-a and -b in several tumor cell lines and the combination of ADI‑PEG 20 and PD-1/PD-L1 blockade abrogated tumorigenesis in a murine model according to research presented by a group from Barts Cancer Institute, London …
Polaris Group’s ADI‑PEG 20 Shows Promising Clinical Activity in NSCLC When Combined with Standard First Line Chemotherapy Regimen
NewsSAN DIEGO, January 10, 2018 – Polaris Group announced today that the combination of its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) with the standard first-line chemotherapy cisplatin + pemetrexed doublet (PemCis) has shown promising clinical activity in an ongoing phase 1 study cohort of non-squamous non-small cell lung carcinoma (NSCLC) patients…
Polaris Announces Results of a Phase 2 Trial of ADI‑PEG 20 in Relapsed/Refractory or Poor-risk Acute Myeloid Leukemia
NewsSAN DIEGO, September 12, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) demonstrated a good safety profile and an efficacy signal as monotherapy in a phase 2 trial in relapsed/refractory or poor-risk acute myeloid leukemia (AML) patients, as reported in the journal Scientific…
Polaris Group Announces Treatment of First Patient in Phase 2/3 Study of ADI‑PEG 20 Plus Cisplatin and Pemetrexed in Malignant Pleural Mesothelioma
NewsSAN DIEGO, August 2, 2017 – Polaris Group announced today that the first patient has been dosed in its randomized, placebo-controlled, double blind phase 2/3 trial (ATOMIC-meso) in malignant pleural mesothelioma (MPM) patients. Patients will be randomized to receive ADI‑PEG 20 (pegylated arginine deiminase) or placebo in combination with pemetrexed…
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 Plus Pembrolizumab in Advanced Solid Tumors
NewsSAN DIEGO, July 14, 2017 – Polaris Group announced today that the first patient has been dosed in its phase 1 trial of ADI‑PEG 20 in combination with pembrolizumab for the treatment of advanced solid tumors. In addition to a global phase 2/3 trial in malignant plural mesothelioma featuring ADI‑PEG…
Polaris Lead Therapeutic ADI‑PEG 20 in Combination with First Line Chemotherapy Is Active in Argininosuccinate Synthetase Deficient Mesothelioma
NewsSAN DIEGO, June 5, 2017 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination with pemetrexed and cisplatin (ADIPemCis) is active in argininosuccinate synthetase (ASS1) deficient malignant pleural mesothelioma (MPM), including non-epithelioid MPM, which carries an unfavorable prognosis and historically responds poorly to…